Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Geneviève I.C.G. Ector, Inge G. P. Geelen, Avinash G. Dinmohamed, Mels Hoogendoorn, Peter E. Westerweel, Rosella P.M.G. Hermens & Nicole M.A. Blijlevens. (2023) Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands. Leukemia & Lymphoma 64:2, pages 424-432.
Read now
Read now
Guangying Sheng, Suning Chen, Ri Zhang, Miao Miao, Depei Wu, Seng Chuen Tan, Chao Liu & Tengbin Xiong. (2017) The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China. Journal of Medical Economics 20:4, pages 382-387.
Read now
Read now
Fausto R. Loberiza$suffix/text()$suffix/text(), Andrew C. Cannon, Anthony J. Cannon & Philip J. Bierman. (2014) Insights on practice variations in the management of lymphoma and leukemia. Leukemia & Lymphoma 55:11, pages 2449-2456.
Read now
Read now
Mansoor N. Saleh, Sally Haislip, Joyce Sharpe, Tamara Hess, James Gilmore, James Jackson, Kavita R. Sail, Solveig G. Ericson & Lei Chen. (2014) Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. Current Medical Research and Opinion 30:4, pages 529-536.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. Journal of Medical Economics 17:2, pages 89-98.
Read now
Read now
Stuart L. Goldberg, Lei Chen, Annie Guerin, Alexander R. Macalalad, Nathan Liu, Michael Kaminsky, Solveig G. Ericson & Eric Q. Wu. (2013) Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Current Medical Research and Opinion 29:9, pages 1075-1082.
Read now
Read now
Articles from other publishers (15)
Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Jessica M. Stempel, Lourdes M. Mendez, Mengyang Di, Xiaomei Ma & Nikolai A. Podoltsev. (2023) Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 7:13, pages 3213-3224.
Crossref
Crossref
Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Crossref
Ehab Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2, pages 19-29.
Crossref
Crossref
Qian Jiang, Lu Yu & Robert Peter Gale. (2018) Patients’ and hematologists’ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 144:4, pages 735-741.
Crossref
Crossref
Stuart L. Goldberg, Jorge E. Cortes, Carlo Gambacorti-Passerini, Rüdiger Hehlmann, H. Jean Khoury, Mauricette Michallet, Ron L. Paquette, Bengt Simonsson, Teresa Zyczynski, Aimee Foreman, Elisabetta Abruzzese, David Andorsky, Aart Beeker, Pascale Cony-Makhoul, Richard Hansen, Elza Lomaia, Eduardo Olavarria & Michael J. Mauro. (2017) First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology 92:11, pages 1214-1223.
Crossref
Crossref
Jorge Enrique Machado-Alba & Manuel Enrique Machado-Duque. (2017) Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia. International Journal of Clinical Pharmacy 39:4, pages 851-859.
Crossref
Crossref
Dominick Latremouille-Viau, Annie Guerin, Patrick Gagnon-Sanschagrin, Katherine Dea, Benjamin G. Cohen & George J. Joseph. (2017) Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Journal of Managed Care & Specialty Pharmacy 23:2, pages 214-224.
Crossref
Crossref
Gabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, Franck E. Nicolini, Frédéric Maloisel, Valérie Coiteux, Charles Dauriac, Nathalie Carpentier, Isabelle Bourdeix, Michel Tulliez & Pascale Cony-Makhoul. (2016) Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study. British Journal of Haematology 174:1, pages 71-80.
Crossref
Crossref
Qian Jiang & Robert Peter Gale. (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. Journal of Cancer Research and Clinical Oncology 142:7, pages 1549-1555.
Crossref
Crossref
Daniel Egan & Jerald Radich. (2016) Monitoring disease burden in chronic myeloid leukemia: Past, present, and future. American Journal of Hematology 91:7, pages 742-746.
Crossref
Crossref
Stuart L. Goldberg. (2015) Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities. Clinical Lymphoma Myeloma and Leukemia 15:12, pages 711-714.
Crossref
Crossref
Nicholas J. Di Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt & Elias J. Jabbour. (2015) The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clinical Lymphoma Myeloma and Leukemia 15:10, pages 599-605.
Crossref
Crossref
Harry P. Erba. (2015) Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission. American Journal of Hematology 90:3, pages 242-249.
Crossref
Crossref
Henry J. Henk, Mabel Woloj, Mark Shapiro & Jennifer Whiteley. (2015) Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States. Clinical Therapeutics 37:1, pages 124-133.
Crossref
Crossref
Daniel J. DeAngelo, Lei Chen, Annie Guerin, Amy Styles, Philippe Giguere-Duval & Eric Q. Wu. (2014) Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. Clinical Lymphoma Myeloma and Leukemia 14:3, pages 245-251.
Crossref
Crossref